ALK inhibitors for ALK-altered paediatric malignancies

Lancet Oncol. 2021 Dec;22(12):1646-1648. doi: 10.1016/S1470-2045(21)00608-2. Epub 2021 Nov 12.

Authors

Laurence Brugieres¹, Zeinab Afify², Eric Lowe³

Affiliations

¹ Department of Oncology for Children and Adolescents, Gustave Roussy Cancer Center, Paris-Saclay University, 94805 Villejuif, France. Electronic address: [email protected].
² Division of Hematology/Oncology, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
³ Division of Pediatric Hematology-Oncology, Children's Hospital of the Kings Daughter, Norfolk, VA, USA.

PMID: 34780708
DOI: 10.1016/S1470-2045(21)00608-2

No abstract available

Publication types

Comment

MeSH terms

Anaplastic Lymphoma Kinase / genetics
Child
Humans
Neoplasms* / drug therapy
Neoplasms* / genetics
Protein Kinase Inhibitors* / adverse effects

Substances

Protein Kinase Inhibitors
Anaplastic Lymphoma Kinase